Author:
Tal-Singer Ruth,Walsh Linda,Deuby Tim,Shaughnessy Angela,Hoth Karin F,Gascon Victor,Hintringer Susanne,Hass Nicole,Winders Tonya,Morgan Lucy,Thomashow Byron,Mannino David M
Abstract
The 2021 purchase of the respiratory pharmaceutical company Vectura by Phillip Morris International has been criticised by the public health and medical community, as a conflict of interest, with little input to date, from the patient community or the public. To address this gap, the COPD Foundation, along with global partners, surveyed 1196 people with chronic respiratory disease. 70% were bothered by a tobacco company making an inhaler to treat lung conditions and 48% reported that they would want to switch inhalers if they knew that a tobacco company made or sold their inhaler devices. Patients care about who makes the therapies used to treat their diseases.
Subject
Pulmonary and Respiratory Medicine
Reference9 articles.
1. Philip morris international purchases vectura;Burki;Lancet Respir Med,2021
2. Adapting Inhaled Medication Practice in COPD and Asthma to Avoid Funding the Tobacco Industry
3. Hopkinson NS . Vectura and Philip Morris: the leopard has not changed its spots. Thorax 2021;16 doi:10.1136/thoraxjnl-2021-218328
4. University of Bath . E-Cigarettes, 2022. Available: https://tobaccotactics.org/wiki/e-cigarettes/ [Accessed 04 June 2022].
5. Asthma + Lung UK . Inhalers for asthma, COPD and other lung conditions: patient information regarding inhaler links to tobacco industry, 2022. Available: https://www.blf.org.uk/sites/default/files/PMI%20Vectura%20patient%20info%20FINAL.pdf [Accessed 04 June 2022].
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献